Neurology 2002;59:529-536
© 2002 American Academy of Neurology
Homocysteine, MTHFR 677C T polymorphism, and risk of ischemic stroke
Results of a meta-analysis
P. J. Kelly, MB MRCPI,
J. Rosand, MD,
J. P. Kistler, MD,
V. E. Shih, MD,
S. Silveira, BA,
A. Plomaritoglou, MD and
K. L. Furie, MD MPH
From the Stroke Service (Drs. Kelly, Rosand, Kistler, Plomaritoglou, and Furie and S. Silveira) and the Amino Acid Laboratory (Dr. Shih), Department of Neurology, Massachusetts General Hospital and Harvard University, Boston.
Address correspondence and reprint requests to Dr. Kelly, Stroke Service, Department of Neurology, VBK 802, Massachusetts General Hospital, Fruit Street, Boston, MA 02114; e-mail: pjkelly{at}partners.org
Background: Data are conflicting concerning risk for ischemic stroke associated with hyperhomocyst(e)inemia (hyper-Hcy) and a common polymorphism in the gene encoding 5,10-methylenetetrahydrofolate reductase (MTHFR 677C T), which predisposes to hyper-Hcy in vivo.
Methods: Search of MEDLINE, Science Citation Index, and abstracts of conference proceedings revealed relevant articles. Exposure was defined as follows: 1) prevalence of hyper-Hcy; 2) absolute difference in the mean Hcy concentration between subjects with and without ischemic stroke; and 3) the MTHFR TT genotype frequency. Outcome was defined as ischemic stroke with or without neuroimaging. Inclusion criteria were retrospective and prospective studies with reported odds ratios (OR) or hazard ratios (HR) or arithmetic mean Hcy levels. Exclusion criteria were absence of OR or HR, outcome defined as carotid atherosclerosis or intima–media thickening, stroke in patients younger than 18 years old, and studies in languages other than English. Statistical analyses for between-study heterogeneity and pooled risk estimates were performed using Stata software (Stata Corporation, College Station, TX).
Results: Among 16 studies (1,487 stroke and 2,554 nonstroke cases), the pooled mean Hcy level in patients with ischemic stoke was 2.32 µmol/L (95% CI, 1.6 to 3.04; p < 0.001) greater than that in those without ischemic stroke. Among 14 included studies (1,769 stroke and 7,400 nonstroke cases), the pooled OR estimate of ischemic stroke associated with hyper-Hcy was 1.79 (95% CI, 1.61 to 2.0; p < 0.001). Among 19 included studies (2,788 stroke and 3,962 nonstroke cases), the OR associated with the TT genotype was 1.23 (95% CI, 0.96 to 1.58; p = 0.1).
Conclusion: These data support an association between mild-to-moderate hyper-Hcy and ischemic stoke. The MTHFR TT genotype may have a small influence in determining susceptibility to ischemic stoke.
This article has been cited by other articles:
|
|
|
|
 
G. Tietjen, N. Herial, C Utley, L White, S Yerga-Woolwine, and B Joe
Association of von Willebrand Factor Activity with ACE I/D and MTHFR C677T Polymorphisms in Migrainecha
Cephalalgia,
September 1, 2009;
29(9):
960 - 968.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Folstein, T. Liu, I. Peter, J. Buel, L. Arsenault, T. Scott, and W. W. Qiu
The Homocysteine Hypothesis of Depression
Am J Psychiatry,
June 1, 2007;
164(6):
861 - 867.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Di Rocco, P. Werner, R. B. Postuma, and A. E. Lang
VITAMINS AND ENTACAPONE IN LEVODOPA-INDUCED HYPERHOMOCYSTEINEMIA: A RANDOMIZED CONTROLLED STUDY
Neurology,
April 24, 2007;
68(17):
1440 - 1441.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Vagiakou, K. A. Voudris, Y. Dimitriou, A. Skardoutsou, and S. Mastroyianni
Different Additional Risk Factors for Cerebral Infarctions Associated With the Factor V Leiden Mutation in a Family
J Child Neurol,
October 1, 2006;
21(10):
903 - 907.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A Pezzini, M Grassi, E Del Zotto, D Assanelli, S Archetti, R Negrini, L Caimi, and A Padovani
Interaction of homocysteine and conventional predisposing factors on risk of ischaemic stroke in young people: consistency in phenotype-disease analysis and genotype-disease analysis
J. Neurol. Neurosurg. Psychiatry,
October 1, 2006;
77(10):
1150 - 1156.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B. Postuma, A. J. Espay, C. Zadikoff, O. Suchowersky, W.R.W. Martin, A. -L. Lafontaine, R. Ranawaya, R. Camicioli, and A. E. Lang
Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: A randomized controlled study
Neurology,
June 27, 2006;
66(12):
1941 - 1943.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Feinbloom and K. A. Bauer
Assessment of Hemostatic Risk Factors in Predicting Arterial Thrombotic Events
Arterioscler Thromb Vasc Biol,
October 1, 2005;
25(10):
2043 - 2053.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Cronin, K. L. Furie, and P. J. Kelly
Dose-Related Association of MTHFR 677T Allele With Risk of Ischemic Stroke: Evidence From a Cumulative Meta-Analysis
Stroke,
July 1, 2005;
36(7):
1581 - 1587.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Van Guelpen, J. Hultdin, I. Johansson, B. Stegmayr, G. Hallmans, T. K. Nilsson, L. Weinehall, C. Witthoft, R. Palmqvist, and A. Winkvist
Folate, Vitamin B12, and Risk of Ischemic and Hemorrhagic Stroke: A Prospective, Nested Case-Referent Study of Plasma Concentrations and Dietary Intake
Stroke,
July 1, 2005;
36(7):
1426 - 1431.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. B. Sobol, E. Bald, and J. Loba
Fractions of Total Plasma Homocysteine in Patients with Ischemic Stroke Before the Age of 55 Years
Angiology,
March 1, 2005;
56(2):
201 - 209.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Pezzini, M. Grassi, E. D. Zotto, S. Archetti, R. Spezi, V. Vergani, D. Assanelli, L. Caimi, and A. Padovani
Cumulative Effect of Predisposing Genotypes and Their Interaction With Modifiable Factors on the Risk of Ischemic Stroke in Young Adults
Stroke,
March 1, 2005;
36(3):
533 - 539.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Frederiksen, K. Juul, P. Grande, G. B. Jensen, T. V. Schroeder, A. Tybjaerg-Hansen, and B. G. Nordestgaard
Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and case-control studies from the Copenhagen City Heart Study
Blood,
November 15, 2004;
104(10):
3046 - 3051.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B. Postuma and A. E. Lang
Homocysteine and levodopa: Should Parkinson disease patients receive preventative therapy?
Neurology,
September 14, 2004;
63(5):
886 - 891.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J. Hankey and J. W. Eikelboom
Folic Acid-Based Multivitamin Therapy to Prevent Stroke: The Jury Is Still Out
Stroke,
August 1, 2004;
35(8):
1995 - 1998.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Voetsch and J. Loscalzo
Genetic Determinants of Arterial Thrombosis
Arterioscler Thromb Vasc Biol,
February 1, 2004;
24(2):
216 - 229.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
D. G. Hackam and S. S. Anand
Emerging Risk Factors for Atherosclerotic Vascular Disease: A Critical Review of the Evidence
JAMA,
August 20, 2003;
290(7):
932 - 940.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. El-Khairy, S. E. Vollset, H. Refsum, and P. M. Ueland
Plasma Total Cysteine, Mortality, and Cardiovascular Disease Hospitalizations: The Hordaland Homocysteine Study
Clin. Chem.,
June 1, 2003;
49(6):
895 - 900.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Kelly, V. E. Shih, J. P. Kistler, M. Barron, H. Lee, R. Mandell, and K. L. Furie
Low Vitamin B6 but Not Homocyst(e)ine Is Associated With Increased Risk of Stroke and Transient Ischemic Attack in the Era of Folic Acid Grain Fortification
Stroke,
June 1, 2003;
34
(6):
e51 - e54.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. B. Fallon, J. Virtamo, I. Young, D. McMaster, Y. Ben-Shlomo, N. Wood, A. S. Whitehead, and G. D. Smith
Homocysteine and Cerebral Infarction in Finnish Male Smokers
Stroke,
June 1, 2003;
34(6):
1359 - 1363.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. B. Fallon, Y. Ben-Shlomo, P.J. Kelly, J. Rosand, V. Shih, J. Kistler, and K.L. Furie
Homocysteine, MTHFR 677C->T polymorphism, and risk of ischemic stroke: Results of a meta-analysis
Neurology,
February 11, 2003;
60(3):
526 - 527.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Alberts
Stroke Genetics Update
Stroke,
February 1, 2003;
34(2):
342 - 344.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P.J. Kelly, K.L. Furie, J.P. Kistler, M. Barron, E.H. Picard, R. Mandell, and V.E. Shih
Stroke in young patients with hyperhomocysteinemia due to cystathionine beta-synthase deficiency
Neurology,
January 28, 2003;
60(2):
275 - 279.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. L Ruberg and J. Loscalzo
Prothrombotic determinants of coronary atherothrombosis
Vascular Medicine,
November 1, 2002;
7(4):
289 - 299.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Homocysteine, MTHFR 677C->T Polymorphism, and Ischemic-Stroke Risk
Journal Watch Neurology,
October 24, 2002;
2002(1024):
3 - 3.
[Full Text]
|
|
|
Correspondence:
Read all Correspondence
- Homocysteine, MTHFR 677CT polymorphism, and risk of ischemic stroke: Results of a
- Una Fallon, et al.
- Neurology Online, 13 Nov 2002
[Full text]
- Reply to Letter to the Editor
- Peter J Kelly, et al.
- Neurology Online, 13 Nov 2002
[Full text]
|
